neuroClues

🔥 We are so excited to share with you that NeuroClues™ is amongst the very few promising start-ups (<8%) awarded the prestigious EIC accelerator funding! We are now ready to move to the next phase: demonstrating the clinical use of neuroClues in the diagnosis of Parkinson’s Disease and supporting its early commercial roll-out!   🇪🇺 The European Innovation Council (EIC) is the EU Commission's flagship innovation program to identify, develop and scale up breakthrough technologies and game-changing innovations. The EIC Accelerator provides substantial financial support with grant funding and direct equity investments managed by the EIC Fund. 🚀 This recognition confirms our ambition for NeuroClues™ to become the brain’s stethoscope, supporting 10M patients by 2030. Congratulations to the whole team! We’re on the right track to fulfill our mission, with the support from Institut du Cerveau – Paris Brain Institute and iPEPS The Healthtech Hub. More info on the press release: https://lnkd.in/g5pZPmAH European Innovation Council and SMEs Executive Agency (EISMEA) invest.bw Graph Ventures Pierre de Waha L'Echo Antoine Pouppez Pierre Daye Pierre Pouget Jean-Baptiste de Harenne Marie Dautrebande Camille Verriest Frédérique Boël Florian Guyot Mark Turcksin Alejandra Mejia Philippe Domineaux Valérie Roels Caroline Van den Eynde @Tym Poitou Bao Nguyen Simon Gerard   #EUeic #eicAccelerator #neuroscience #innovationinhealthcare #capitalventure #funding #scaling

🌟We’re Heading to Athens for# ESSEM24! 📚The @European Summer School on Eye Movements (#ESSEM) is an educational event that explores eye movement research, bringing together researchers and students from various fields. ESSEM provides opportunities for networking and learning from leading experts, offering insights into current research methodologies and findings. 🎤Our own Pierre Pouget, co-founder and scientific advisor, will be leading multiple presentations. He'll kick off with an introduction to eye movements, explore animal studies in neuroscience, and conclude with an update on our innovative project, neuroClues—neurologist’s future companion. 🔬Eye movements have been linked to neurological disorders, and having the right tools can transform early diagnosis, treatment, and follow-up. Events like #ESSEM are vital for showcasing the critical role of eye tracking in neurology and the need for advanced diagnostic tools. They hold a special place in our hearts as they help raise awareness about the power of eye tracking. 👁️The eyes reveal so much, let’s take advantage of that. 🤝If you can’t make it to Athens but want to learn more about eye movements, let’s connect! We’d love to discuss. Nikolaos Smyrnis, Chrystalina Antoniades, Giuseppe Boccignone, Olaf Dimigen, Johanna Kaakinen, Kristof Keidel, Päivi Majaranta, Susana Martinez-Conde, Dr. Rima-Maria Rahal #biomarkers #neuroscience #eyetracking * neuroClues is in research & development phase and will soon go through regulatory approval.

🔍 New Horizons in #MS Research with Eye Tracking Technology 🧠 Multiple Sclerosis is a chronic inflammatory neurological disorder affecting approximately 2.8 million people worldwide. It can cause a range of symptoms, including coordination and balance issues, movement disorders, and vision and cognitive impairments.  👀 Since MS can impact various parts of the central nervous system, it’s no surprise that eye movement disorders are commonly observed in MS patients. Given that eye movement circuits encompass multiple brain regions, analyzing eye movements can provide valuable insights into the disease. Here are two recent studies highlighted in our August newsletter:  📄 Suh et al. (2024) reveal how eye-tracking technology can serve as a non-invasive tool to objectively measure saccadic disorders, aiding in early diagnosis, disease monitoring, and treatment evaluation.  📄Nij Bijvank et al. (2023) demonstrate that the double-step saccadic test is a promising alternative for assessing treatment efficacy, compared to traditional single saccadic tests. 🤿 Dive into our full article to see how these innovations could revolutionize MS care. 📩Curious to stay up to date with the latest advancements in eye tracking and MS research? Sign up for our monthly newsletter to get the latest insights and updates delivered straight to your inbox (link in the comments)  Sam Hof,  Menno Schoonheim,Alex Suh,  Gilad Hampel,   Aditya Vinjamuri,  Nasif Zaman,  Alireza Tavakkoli Andrew Lee MS Canada MSPLUS FOUNDATION EMSP - European Multiple Sclerosis Platform MS Society National MS Society Multiple Sclerosis Foundation Multiple Sclerosis Association of America (MSAA) Multiple Sclerosis Ireland #biomarkers #eyetracking #neuroscience * neuroClues is in research & development phase and will soon go through regulatory approval. 

💔 Detecting heart failures through the pupils 🏥 Heart failure (HF) is the primary reason for hospital admissions among people over 65, comprising 1-2% of hospitalizations in Western nations. With over 60 million affected worldwide, HF significantly impacts healthcare costs and patient quality of life on a global scale. 🫀#HF occurs when the heart cannot generate sufficient cardiac output to meet the body's metabolic demands. This condition triggers neurohormonal responses, including the activation of the sympathetic nervous system (#SNS) and the subsequent release of adrenaline and noradrenaline. These hormones interact with adrenergic receptors in the iris, leading to pupillary dilation. 👀 In their study, Zamorano et al. (2024) explore the potential of pupillometry as a tool and discover that patients with decompensated heart failure exhibit larger baseline pupil diameters and faster pupil dilation velocities compared to healthy controls, indicating SNS hyperactivation. 🩺These findings suggest that pupillometry offers a non-invasive, simple, and cost-effective method for assessing SNS activity and predicting prognosis in HF patients, thereby improving patient care and management. #biomarkers #neuroscience #eyetracking @Margarita Zamorano, @Juan Manuel Monteagudo, @Eduardo González , @Isabel Rayo, Sara Fra Fernández , @Miguel Castillo, @Qiheng Zhou, @Pedro de la Villa, @Jose Luis Zamorano Hospital Ramón y Cajal Hospital Universitario Ramón y Cajal Universidad de Alcalá European Society of Cardiology Heart Failure Society of America American Heart Association British Society for Heart Failure Canadian Heart Failure Society * These statements are not neuroClues product-specific claims but scientifically backed evidence of the clinical relevance of eye tracking

 “I think that we highlighted the clinical value of ocular motor dysfunction in corticobasal syndrome (#CBS)” stated Jacy Parmera on the International Parkinson and Movement Disorder Society podcast 🍀 CBS is a rare neurological condition affecting about 5 in 100,000 people. It typically begins with movement difficulties on one side of the body, such as stiffness or impaired control of an arm or leg. As it progresses, symptoms can spread to both sides and include cognitive and behavioural changes. 🔍CBS can arise from conditions like corticobasal degeneration (#CBD), Alzheimer’s disease (#AD), and progressive supranuclear palsy (#PSP), which have overlapping symptoms that make differentiation challenging. 🩺 Identifying abnormal eye movement patterns in CBS could serve as a crucial clinical indicator. These ocular motor dysfunctions might help pinpoint the underlying cause of CBS, particularly for 4-R tauopathies such as corticobasal degeneration (CBD) or progressive supranuclear palsy (PSP) Why is understanding the underlying condition crucial? ❓Treatment: Treatment for CBS varies with the underlying pathology; incorrect treatment can result in poor outcomes and missed opportunities for personalized care. ❓Prognosis: Accurate identification of the underlying condition allows healthcare providers to offer better prognostic information, aiding in future care planning. 🚀At neuroClues, we are dedicated to developing the neurologist’s companion: a tool that empowers them in providing a better diagnosis and improved follow-up of neurological conditions. Michele Matarazzo, Isabel Junqueira de Almeida, Marcos Castello Barbosa de Oliveira ,  Carlos Buchpiguel , Artur Martins N. Coutinho USP - Universidade de São Paulo #biomarkers #neuroscience #eyetracking  * neuroClues is in research & development phase and will soon go through regulatory approval.

💫 Eye movements can provide valuable insights into sensory processing challenges faced by individuals with autism spectrum disorder (ASD) 🌎 According to the Centers for Disease Control and Prevention, about 1% of the global population—over 75 million people—has #ASD. This neurodevelopmental condition affects social interaction, communication, and behavior, with severity ranging from needing significant support to functioning independently. 🧠 During a saccade, an efference copy is generated to predict where visual stimuli will land on the retina, helping maintain stable perception. If these predictions don't match reality, it can lead to sensory mismatches and overload, as the brain tries to make sense of the conflicting information, a common symptom in ASD. 🔍 Pomè & Zimmermann (2024) found that individuals with higher autistic traits showed significant challenges in updating their mental map, which led to errors in object localization. Additionally, the study revealed that these individuals exhibited a larger error in perceiving object movement, indicating that they struggled more with adjusting for their eye movements and maintaining spatial stability. 👀Eye tracking technology offers precise measurements of eye positions and movements, allowing for a deeper understanding the relationship between eye movements, efference copy, and sensory overload. This insight can lead to better ways to help autistic individuals process and respond to sensory information. By focusing on these specific mechanisms, pharmaceutical companies could create therapies that enhance predictive abilities and reduce sensory sensitivities. Antonella Pomè @Eckart Zimmermann University of Düsseldorf #biomarkers #eyetracking #neuroscience #autismspectrumdisorder #autism  * neuroClues is in research & development phase and will soon go through regulatory approval.

🏅Aux Jeux Olympiques, où les chocs à la tête sont fréquents, il est crucial d'améliorer la gestion des commotions cérébrales: les mouvements oculaires pourraient offrir une piste prometteuse. 🚨La tribune publiée dans Le Monde souligne l'urgence d'améliorer la détection et la gestion des commotions cérébrales, un problème souvent qualifié d'« épidémie silencieuse ». En France, ces blessures touchent chaque année au moins 100 000 personnes, mais une grande partie n'est ni recensée ni correctement prise en charge. 🧠 Une commotion cérébrale, définie comme une traumatisme crânien léger, survient à la suite d'un choc à la tête, provoquant un déplacement rapide du cerveau à l'intérieur du crâne. Ce mouvement peut endommager les cellules cérébrales et entraîner des modifications chimiques. Bien qu’elles soient qualifiées de "légères", leur diagnostic est loin d'être simple. Les symptômes peuvent apparaître tardivement et dépendent largement des témoignages des patients. Pour cette raison, la recherche d'outils de diagnostic plus objectifs est cruciale. 👁️Les mouvements oculaires offrent une solution prometteuse pour une évaluation rapide et objective des commotions cérébrales. Les mesures des performances oculaires peuvent servir de biomarqueurs fiables. Découvrez la retranscription vidéo de Kevin Polet (neuropsychologue, Centre Princesse Grace) sur ce sujet, présentée lors de notre Cocktail Scientifique (lien en commentaires). 🤝Chez neuroClues, nous visons à aider les cliniciens avec un outil de quantification objective des mouvements oculaires pour améliorer l’évaluation et le suivi des commotions cérébrales. Nous soutenons l'initiative de sensibilisation, convaincus que ces avancées permettront une meilleure compréhension et gestion des commotions, pour une prise en charge plus efficace. Guillaume Blivet Renaud DAVID Patrice CRISTOFINI Kélian Galletier Philippe Malafosse Frédéric Mistretta Serge Monneret yves Pagès Dr Marc Rozenblat Philippe SELLA Antoine Semeria Michel Taube Jacques Touchon Franck ASSABAN Florent Roger Centre Hospitalier Universitaire de Nice (CHU de Nice) FFF - Fédération Française de Football Greater Paris University Hospitals - AP-HP Société Française de Neurologie Société Française de Sport-Santé (SF2S) ALERTE COMMOTIONS University of Montpellier UNFP Union Nationale des Footballeurs Professionnels #biomarkers #neuroscience #eyetracking * neuroClues est une marque déposée de P3Lab, actuellement en phase de recherche et de développement. Elle sera disponible à la vente lorsque l'autorisation réglementaire aura été obtenue.

👁️ Eye movements are pivotal in diagnosing movement disorders, as emphasized by Kassavetis et al. (2022) in the International Parkinson and Movement Disorder Society's Movement Disorders Clinical Practice issue. Their review underscores how abnormalities in eye movement patterns can reveal valuable information about various neurological conditions, including Parkinson's disease, ataxia, and dystonia. Eye movements involve complex neural mechanisms, and recent advancements have enhanced neuroscientists' and clinicians' understanding of their role in both ocular and limb movement issues. They can provide:  🧠 Diagnostic insights: For instance, subtle signs like square wave jerks* in parkinsonism can suggest early progressive supranuclear palsy. 🧠 Differential diagnosis: For example, gaze impersistence** may indicate Huntington’s disease, while nystagmus*** is common in ataxia. 🩺 Recognizing and evaluating eye movement abnormalities can help practitioners provide more accurate assessments and improved patient outcomes in movement disorders. By developing neuroClues, our ambition is to empower neurologists in their work. 🤝Interested in discussing eye movement science or sharing new research? Let’s connect and dive into the conversation! *Square wave jerk: small horizontal saccades away from a fixation point, followed by a corrective saccade back to the fixation, occurring with an intersaccadic interval of about 200 milliseconds ** gaze impersistence: inability to maintain fixation by suppressing reflexive saccades to stimuli that appear in the visual field. ***nystagmus: abnormal eye movement characterized by a slow phase that takes the eye away from fixation, followed by a fast phase that is a restorative saccade back toward the intended fixation point .   Panagiotis Kassavetis, MD, MSc, PhD- Diego Kaski - @Tim Anderson - @Mark Hallet #biomarkers #eyetracking #neuroscience * neuroClues is in research & development phase and will soon go through regulatory approval.

Our Head of Sales, Heather Keith, is at Alzheimer's Association® International Conference this week! 🎉Let's connect and discuss how eye movements can aid in the early diagnosis and treatment of Alzheimer's disease. #AAIC24 #biomarkers #eyetracking #neuroscience #AAIC

✈️Our team is attending the next #AAIC24 meeting in Philadelphia!  🌎The Alzheimer's Association® International Conference (#AAIC) is the largest and most influential global meeting dedicated to advancing dementia science. It brings together the world's leading researchers, clinicians, and care professionals to share groundbreaking research and innovative ideas to improve the understanding and treatment of Alzheimer's disease and related dementias. 📚 Studies suggest that eye-tracking, by detecting early deficits in eye movement control and error correction due to frontal and parietal lobe degeneration, can identify Alzheimer’s Disease and other dementias like Fronto-Temporal Dementia (#FTD), Parkinson’s Disease Dementia (#PDD), and Dementia with Lewy Bodies (#DLB) in the preclinical stage, potentially improving diagnostic precision and effectiveness. Our head of sales-Heather Keith and business developer- Valentin Van Cauwenberg would love to connect with you and discuss our project: an all-in-one eye tracking assistant, designed by clinicians to bring the wealth of eye movements into the consultation. #biomarkers #neuroscience #eyetracking * neuroClues is in research & development phase and will soon go through regulatory approval.